NWBO 最新10-Q变化
将 NWBO 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-15
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +27 | −15 | ~17 | 18 |
| 市场风险(第3项) | 文字有新增/删除 | +2 | −1 | ~1 | 3 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
| 法律诉讼 | 文字有新增/删除 | +1 | 0 | 0 | 10 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):风险因素、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Collaborations. The Company pursued collaboration discussions in certain countries where the Company believes that development and potential commercialization could proceed more rapidly and efficiently with a partner. As previously reported, the Company entered into an MOU for a potential collaborat…
Statistical Analyses and BNOS Presentation. As previously reported, the Company worked closely with a team of independent statisticians to analyze the data from the Phase 3 trial of DCVax-L for glioblastoma, applying multiple statistical methodologies and using individual patient data (IPD) comparat…
UK Leukapheresis Capacity. The Company continued it efforts to develop expanded capacity for leukapheresis procedures. The Company pursued discussions with certain parties who have existing leukapheresis facilities, to secure further capacity without capital expenditure. In parallel, the Company als…
UK Manufacturing Capacity. The Company began exploring the potential for conducting the tumor lysate stage of the manufacturing process in additional facilities to enable an increase in the production capacity in the Sawston facility before the completion of the Grade C lab. The Company continued di…
another region of the UK, using an existing established GMP facility. The Company also pursued a grant funding program for non-dilutive capital for development of capacity in the Sawston facility.
相对上期删除的文字 · 来源:10-Q · 2026-05-15
UK Strategic Advisor. As previously reported, the Company engaged a new Strategic Advisor, Dr. Annalisa Jenkins. Dr. Jenkins has extensive experience in big pharma, biotech and medical innovation, and is a key opinion leader in the UK and globally. Dr. Jenkins will advise and help the Company advanc…
UK Clinic. As also previously reported, the Company’s pursuit of clinic arrangements or collaborations in the UK culminated in the Company establishing a clinic arrangement with the London Welbeck Hospital in the Harley Street medical district in London. During the first quarter, the Company secured…
Development of the Sawston, UK Facility. The Company and Advent continued the development process for the initial Grade C lab in the Sawston facility. The Company and Advent worked with advisers and the construction firm to modify the C lab design so as to increase its capacity and enable faster pac…
Secondary Manufacturing in the UK. The Company continued discussions for a collaboration that could potentially lead to a second DCVax production operation in another region of the UK, using an existing established GMP facility with training of the personnel to be conducted by Advent. Since this sec…
Company anticipates that it could be brought online rapidly and economically. The Company is pursuing planning discussions with the party in charge of the facility.
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-08-14
The primary quantifiable market risk associated with our financial instruments is sensitivity to changes in interest rates. Interest rate risk represents the potential loss from adverse changes in market interest rates. We use an interest rate sensitivity simulation to assess our
interest rate risk exposure. For purposes of presenting the possible earnings effect of a hypothetical, adverse change in interest rates over the 12-month period from our reporting date, we assume that all interest rate sensitive financial instruments will be impacted by a hypothetical, immediate 10…
相对上期删除的文字 · 来源:10-Q · 2026-05-15
The primary quantifiable market risk associated with our financial instruments is sensitivity to changes in interest rates. Interest rate risk represents the potential loss from adverse changes in market interest rates. We use an interest rate sensitivity simulation to assess our interest rate risk …
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-08-14
During the second quarter of 2026, the Company continued vigorously pursuing discovery in its litigation in New York against certain market makers. Among other steps, the Company continued seeking certain trading information and trading algorithms. The Company believes that the Court’s recent order …
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议